SecBot SecBot
SECBOTREPLAY Home › Report › ERAS

ERAS · Erasca reported highly positive preliminary Phase 1 data for pan-RAS…

Erasca, Inc. · PRESS-RELEASE filed Apr 27, 2026 at 16:01 ET

At the news

BULLISHIMPACT 8/10

PRESS-RELEASE filed Apr 27, 2026 at 16:01 ET

Erasca reported highly positive preliminary Phase 1 data for pan-RAS inhibitor ERAS-0015, showing 62% uORR in 2L+ KRAS G12X NSCLC (vs 38% for comparator RMC-6236) and 40% uORR in 2L PDAC (vs 29% comparator), with favorable safety. This is a major catalyst for the stock, potentially positioning ERAS-0015 as best-in-class.

  • 62% uORR in 2L+ KRAS G12X NSCLC at PAD 16-32 mg QD vs 38% comparator
  • 75% uORR in post-ICI/platinum 2/3L NSCLC at PAD vs 38% comparator
  • 40% uORR in 2L KRAS G12X PDAC at PAD vs 29% comparator
  • No DLTs, low-grade AEs, no discontinuations due to TRAEs

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access